Precipio (NASDAQ:PRPO) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Precipio (NASDAQ:PRPO) from a hold rating to a buy rating in a report released on Thursday, ValuEngine reports.

NASDAQ:PRPO traded down $0.06 during trading hours on Thursday, hitting $2.85. 102,654 shares of the stock were exchanged, compared to its average volume of 165,801. Precipio has a 52-week low of $1.65 and a 52-week high of $10.80. The business’s fifty day simple moving average is $3.17. The company has a current ratio of 0.14, a quick ratio of 0.13 and a debt-to-equity ratio of 0.09.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings data on Thursday, May 16th. The biotechnology company reported ($0.48) EPS for the quarter. The firm had revenue of $0.71 million for the quarter. Precipio had a negative return on equity of 92.71% and a negative net margin of 533.37%.

A hedge fund recently bought a new stake in Precipio stock. SeaCrest Wealth Management LLC acquired a new stake in shares of Precipio (NASDAQ:PRPO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,300 shares of the biotechnology company’s stock, valued at approximately $184,000. SeaCrest Wealth Management LLC owned about 0.92% of Precipio as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.68% of the company’s stock.

About Precipio

Precipio, Inc, a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer.

See Also: Golden Cross

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.